{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:59:08Z","timestamp":1780523948125,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anaplastic thyroid carcinoma (ATC) exhibits an exceedingly poor prognosis, and the current treatment options are, for most cases, palliative by nature. Few reports of long-time survivors exist, although in these patients, tumors often were limited to the thyroid and\/or regional lymph nodes. We describe a 64-year-old male who developed a rapidly growing mass in the left thyroid lobe. A fine-needle aspiration biopsy (FNAB) was consistent with ATC, and the patient underwent preoperative combined chemo- and radiotherapy followed by a hemithyroidectomy. The ensuing histopathological investigation was consistent with ATC adjoined by an oxyphilic well-differentiated lesion, likely a H\u00fcrthle cell carcinoma. Tumor margins were negative, and no extrathyroidal extension was noted. Focused next-generation sequencing analysis of the primary tumor tissue identified a <jats:italic>TP53<\/jats:italic> gene mutation but could not identify any potential druggable targets. Additional Sanger sequencing detected a C228T <jats:italic>TERT<\/jats:italic> promoter mutation. The tumor was found to be microsatellite stable and displayed PDL1 expression in 80% of tumor cells. Following a CT scan 1\u00a0month postoperatively, metastatic deposits were suspected in the lung as well as in the left adrenal gland, of which FNAB verified the latter. Remarkably, upon radiological follow-up, the disease had gone into apparent complete remission. The patient is alive and well with no signs of residual disease after 12\u00a0months of follow-up. We here summarize the clinical, histological, and molecular data of this highly interesting patient case and review the literature for possible common denominators with other patients with disseminated ATC.<\/jats:p>","DOI":"10.1007\/s12022-020-09606-5","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T07:02:33Z","timestamp":1580713353000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case"],"prefix":"10.1007","volume":"31","author":[{"given":"Adam","family":"Stenman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Samuel","family":"Hellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenbugul","family":"Jatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hysek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Zemmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga-Lena","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Br\u00e4nstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zedenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-9081","authenticated-orcid":false,"given":"C. Christofer","family":"Juhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"9606_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/jso.23177","volume":"106","author":"I Segerhammar","year":"2012","unstructured":"Segerhammar I, Larsson C, Nilsson I-L, B\u00e4ckdahl M, H\u00f6\u00f6g A, Wallin G, Foukakis T, Zedenius J Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. J Surg Oncol. 2012;106:981\u2013986.","journal-title":"J Surg Oncol."},{"key":"9606_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","volume":"79","author":"FD Gilliland","year":"1997","unstructured":"Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79:564\u2013573.","journal-title":"Cancer."},{"key":"9606_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","volume":"13","author":"C Are","year":"2006","unstructured":"Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13:453\u2013464.","journal-title":"Ann Surg Oncol."},{"key":"9606_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103:1330\u20131335.","journal-title":"Cancer."},{"key":"9606_CR5","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","volume":"24","author":"JW Kunstman","year":"2015","unstructured":"Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, H\u00f6\u00f6g A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 2015;24:2318\u20132329.","journal-title":"Hum Mol Genet."},{"issue":"2","key":"9606_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/path.5359","volume":"250","author":"Johan O Paulsson","year":"2019","unstructured":"Paulsson JO, Backman S, Wang N, Stenman A, Crona J, Thutkawkorapin J, et al. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation. J Pathol. 2020;250:183\u2013194.\u00a0","journal-title":"The Journal of Pathology"},{"key":"9606_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera D, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24:3059\u20133068.","journal-title":"Clin Cancer Res."},{"key":"9606_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/mgme.2000.3114","volume":"72","author":"B Shahedian","year":"2001","unstructured":"Shahedian B, Shi Y, Zou M, Farid NR. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab. 2001;72:155\u2013163.","journal-title":"Mol Genet Metab."},{"key":"9606_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00428-018-2386-1","volume":"473","author":"M Hysek","year":"2018","unstructured":"Hysek M, Paulsson JO, Wang N, Jatta K, Lindh C, Fuentes-Martinez N, Shabo I, Zedenius J, Juhlin CC TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine. Virchows Arch. 2018;473:639\u2013643.","journal-title":"Virchows Arch."},{"key":"9606_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/thy.2011.2121","volume":"21","author":"MD Ringel","year":"2011","unstructured":"Ringel MD. Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid. 2011;21:487\u2013492.","journal-title":"Thyroid."},{"key":"9606_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0002-9394(02)01973-6","volume":"135","author":"AM Hammad","year":"2003","unstructured":"Hammad AM, Paris GR, van Heuven WAJ, Thompson IM, Fitzsimmons TD. Spontaneous regression of choroidal metastasis from renal cell carcinoma. Am J Ophthalmol. 2003;135:911\u2013913.","journal-title":"Am J Ophthalmol."},{"key":"9606_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)41730-7","volume":"140","author":"AW Ritchie","year":"1988","unstructured":"Ritchie AW, Layfield LJ, de Kernion JB. Spontaneous regression of liver metastasis from renal carcinoma. J Urol. 1988;140:596\u2013597.","journal-title":"J Urol."},{"key":"9606_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S0022-5347(17)58630-9","volume":"117","author":"JH Deweerd","year":"1977","unstructured":"Deweerd JH, Hawthorne NJ, Adson MA. Regression of renal cell hepatic metastasis following removal of primary lesions. J Urol. 1977;117:790\u2013792.","journal-title":"J Urol."},{"key":"9606_CR14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3892\/ol.2010.176","volume":"1","author":"SB Ricci","year":"2010","unstructured":"Ricci SB, Cerchiari U. Spontaneous regression of malignant tumors: importance of the immune system and other factors (Review). Oncol Lett. 2010;1:941\u2013945.","journal-title":"Oncol Lett."},{"key":"9606_CR15","first-page":"5873897","volume":"2018","author":"J Shim","year":"2018","unstructured":"Shim J, Rao J, Yu R. Spontaneous regression of metastatic papillary thyroid cancer in a lymph node. Case Rep Endocrinol. 2018;2018:5873897.","journal-title":"Case Rep Endocrinol."},{"key":"9606_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF02907810","volume":"3","author":"G Vad\u00e1sz","year":"1997","unstructured":"Vad\u00e1sz G, S\u00e1pi Z, Erdei M, L\u00f6vey G, Bod\u00f3 M. Spontaneously curing anaplastic carcinoma in the lymph node. Pathol Oncol Res POR. 1997;3:139\u2013141.","journal-title":"Pathol Oncol Res POR."},{"key":"9606_CR17","first-page":"3557","volume":"104","author":"R Giannini","year":"2019","unstructured":"Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, Morelli S, Colella R, Mandarano M, Sidoni A, Panfili M, Basolo F, Puxeddu E Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes: an ATC-like and a PDTC-like. J Clin Endocrinol Metab. 2019;104:3557\u20133575.","journal-title":"J Clin Endocrinol Metab."},{"key":"9606_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017;24:97\u2013106.","journal-title":"Endocr Relat Cancer."},{"key":"9606_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/his.13230","volume":"71","author":"K Zwaenepoel","year":"2017","unstructured":"Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, et al. CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy. Histopathology. 2017;71:357\u2013365.","journal-title":"Histopathology."},{"key":"9606_CR20","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00262-019-02416-7","volume":"68","author":"MJ Aghajani","year":"2019","unstructured":"Aghajani MJ, Cooper A, McGuire H, Jeffries T, Saab J, Ismail K, de Souza P, Bray V, Fazekas de St Groth B, Niles N, Roberts TL Pembrolizumab for anaplastic thyroid cancer: a case study. Cancer Immunol Immunother CII. 2019;68:1921\u20131934.","journal-title":"Cancer Immunol Immunother CII."},{"key":"9606_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6:68.","journal-title":"J Immunother Cancer."},{"key":"9606_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","volume":"119","author":"V Gunda","year":"2018","unstructured":"Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018;119:1223\u20131232.","journal-title":"Br J Cancer."},{"key":"9606_CR23","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/ijc.32041","volume":"144","author":"V Gunda","year":"2019","unstructured":"Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, et al. Anti-PD-1\/PD-L1 therapy augments lenvatinib\u2019s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer. 2019;144:2266\u20132278.","journal-title":"Int J Cancer."},{"key":"9606_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/ajcp\/80.3.399","volume":"80","author":"A Bauman","year":"1983","unstructured":"Bauman A, Strawbridge HT. Spontaneous disappearance of an atypical H\u00fcrthle cell adenoma. Am J Clin Pathol. 1983;80:399\u2013402.","journal-title":"Am J Clin Pathol."},{"key":"9606_CR25","doi-asserted-by":"publisher","first-page":"X2","DOI":"10.1530\/ERC-11-0354a","volume":"23","author":"V M\u00e1ximo","year":"2016","unstructured":"M\u00e1ximo V, Lima J, Prazeres H, Soares P, Sobrinho-Sim\u00f5es M. The biology and the genetics of H\u00fcrthle cell tumors of the thyroid. Endocr Relat Cancer. 2016;23:X2.","journal-title":"Endocr Relat Cancer."},{"key":"9606_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/lam.12436","volume":"61","author":"S Wong","year":"2015","unstructured":"Wong S, Slavcev RA. Treating cancer with infection: a review on bacterial cancer therapy. Lett Appl Microbiol. 2015;61:107\u2013112.","journal-title":"Lett Appl Microbiol."},{"key":"9606_CR27","doi-asserted-by":"crossref","unstructured":"Thakur S, Daley B, Klubo-Gwiezdzinska J. The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol. 2019.","DOI":"10.1530\/JME-19-0083"},{"key":"9606_CR28","doi-asserted-by":"publisher","first-page":"E510","DOI":"10.1210\/jc.2011-1754","volume":"97","author":"G Chen","year":"2012","unstructured":"Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012;97:E510\u2013E520.","journal-title":"J Clin Endocrinol Metab."},{"key":"9606_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/s-0029-1224116","volume":"41","author":"C Papewalis","year":"2009","unstructured":"Papewalis C, Wuttke M, Schinner S, Willenberg HS, Baran AM, Scherbaum WA, Schott M Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res. 2009;41:752\u2013756.","journal-title":"Horm Metab Res."},{"key":"9606_CR30","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","volume":"371","author":"N Wagle","year":"2014","unstructured":"Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371:1426\u20131433.","journal-title":"N Engl J Med."}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-020-09606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12022-020-09606-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-020-09606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T01:37:23Z","timestamp":1612229843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12022-020-09606-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["9606"],"URL":"https:\/\/doi.org\/10.1007\/s12022-020-09606-5","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"3 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The patient has given full oral and written consent to the preparation of this case report. In addition, it was approved by the local ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate and Consent for Publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}